2(1H)-Quinolinone, 5-[[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxy-4-piperidinyl]methoxy]-8-fluoro-3,4-dihydro-

Request For Quotation
2(1H)-Quinolinone, 5-[[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxy-4-piperidinyl]methoxy]-8-fluoro-3,4-dihydro- Suppliers list
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354; +17819995354
Email: marketing@targetmol.com
Products Intro: Product Name:OPC-167832
CAS:1883747-71-4
Package:50mg;1530USD|100mg;2440USD|25mg;1170USD
Company Name: Nantong HI-FUTURE Biology Co., Ltd.
Tel: +undefined18051384581
Email: sales@chemhifuture.com
Products Intro: Product Name:OPC-167832
CAS:1883747-71-4
Purity:0.95 Package:5mg，10mg，100mg，500mg，1g，5g，10g，more
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Products Intro: Product Name:OPC-167832
CAS:1883747-71-4
Remarks:Reach out to us for more information about custom solutions.
Company Name: Nantong Hi-Future Biotechnology Co., Ltd  
Tel: 18051384581
Email: sales@chemhifuture.com
Products Intro: Product Name:OPC-167832
CAS:1883747-71-4
Purity:98% HPLC Package:10mg，500mg，1g，5g+
Company Name: TargetMol Chemicals Inc.  
Tel: 4008200310 15002144251
Email: marketing@tsbiochem.com
Products Intro: Product Name:OPC-167832
CAS:1883747-71-4
Purity:98% Package:1removed

2(1H)-Quinolinone, 5-[[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxy-4-piperidinyl]methoxy]-8-fluoro-3,4-dihydro- manufacturers

  • OPC-167832
  • OPC-167832 pictures
  • $1530.00
  • 2026-07-14
  • CAS:1883747-71-4
  • Purity:
  • Supply Ability: 10g
  • OPC-167832
  • OPC-167832 pictures
  • $1530.00
  • 2026-01-05
  • CAS:1883747-71-4
  • Purity:
  • Supply Ability: 10g
2(1H)-Quinolinone, 5-[[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxy-4-piperidinyl]methoxy]-8-fluoro-3,4-dihydro- Basic information
Product Name:2(1H)-Quinolinone, 5-[[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxy-4-piperidinyl]methoxy]-8-fluoro-3,4-dihydro-
Synonyms:2(1H)-Quinolinone, 5-[[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxy-4-piperidinyl]methoxy]-8-fluoro-3,4-dihydro-;Quabodepistat（OPC-167832）;OPC167832,OPC 167832;5-[[(3R,4R)-1-(4-chloro-2,6-difluoro-phenyl)-3,4-dihydroxy-4-piperidyl]methoxy]-8-fluoro-3,4-dihydro-1H-quinolin-2-one;5-(((3R,4R)-1-(4-Chloro-2,6-difluorophenyl)-3,4-dihydroxypiperidin-4-yl)methoxy)-8-fluoro-3,4-dihydroquinolin-2(1H)-one;OPC-167832
CAS:1883747-71-4
MF:C21H20ClF3N2O4
MW:456.84
EINECS:
Product Categories:
Mol File:1883747-71-4.mol
2(1H)-Quinolinone, 5-[[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxy-4-piperidinyl]methoxy]-8-fluoro-3,4-dihydro- Structure
2(1H)-Quinolinone, 5-[[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxy-4-piperidinyl]methoxy]-8-fluoro-3,4-dihydro- Chemical Properties
Boiling point 645.6±55.0 °C(Predicted)
density 1.485±0.06 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO : 180 mg/mL (394.01 mM; Need ultrasonic)
pka13.08±0.40(Predicted)
form Solid
color White to light yellow
Safety Information
MSDS Information
2(1H)-Quinolinone, 5-[[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxy-4-piperidinyl]methoxy]-8-fluoro-3,4-dihydro- Usage And Synthesis
UsesQuabodepistat (OPC-167832) is a potent and orally active dprE1 inhibitor withan IC50 of 0.258 μM. Quabodepistat has antituberculosis activity and can be used for the research of tuberculosiscaused byMycobacterium tuberculosis[1].
in vivo

Quabodepistat (OPC-167832) (oral administration; 0.625-10 mg/kg) exhibits a good pharmacokineticcharacteristic. The plasma reaches peak at 0.5 h to 1.0 h (tmax) and is eliminated with a half-life (t1/2) of 1.3 h to 2.1 hQuabodepistat distribution in the lungs is approximately 2 times higher than that in plasma, and theCmaxand AUCt of Quabodepistat in plasma and the lungs shows dose dependency[1].Quabodepistat (oral administration; 0.625-10 mg/kg; 4weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625mg/kg to 2.5mg/kg. In aM. tuberculosisKurono-infected ICR female mice model. Quabodepistat combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone[1].[1].Quabodepistat (oral gavage; 2.5mg/kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate[1].

Animal Model:ICR mice[1]
Dosage:0.625-10 mg/kg
Administration:Oral administration; 0.625-10 mg/kg; 4weeks
Result:Exhibited in vivoefficacy against a mouse chronic TB model.
References[1] Norimitsu Hariguchi, et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19. DOI:10.1128/AAC.02020-19
2(1H)-Quinolinone, 5-[[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxy-4-piperidinyl]methoxy]-8-fluoro-3,4-dihydro- Preparation Products And Raw materials
Tag:2(1H)-Quinolinone, 5-[[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxy-4-piperidinyl]methoxy]-8-fluoro-3,4-dihydro-(1883747-71-4) Related Product Information